

DAFTAR PUSTAKA

1. CDC. United States Cancer Statistics : Data Visualizations, <https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/> (2019).
2. Hero SK. Faktor Resiko Kanker Payudara. *J Bagus* 2020; 02: 402–406.
3. World Health Organization. Cancer Incident in Indonesia. *WHO* 2020; Int Agency Res Cancer;858:1–2.
4. Elmika E, Adi MS. Gambaran Umur, dan Jenis Kelamin Pasien Kanker Payudara di RS Ibnu Sina Kota Makassar. *J Penelit Kesehatan" SUARA FORIKES"(Journal Heal Res Forikes Voice")* 2020; 11: 422–424.
5. Diana D, Kusmardi. Tumor-infiltrating lymphocytes and their role in breast carcinoma. *Maj Patol Indones* 2020; 29: 30–40.
6. Luthar SS, Cicchetti D, Becker B. The construct of resilience: A critical evaluation and guidelines for future work. *Child Dev* 2000; 71: 543–562.
7. Ingold Heppner B, Loibl S, Denkert C. Tumor-infiltrating lymphocytes: a promising biomarker in breast cancer. *Breast Care* 2016; 11: 96–100.
8. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. *J Natl Cancer Inst*; 109. Epub ahead of print September 2017. DOI: 10.1093/jnci/djx030.
9. Arafah ABR, Notobroto HB. Faktor yang berhubungan dengan perilaku ibu rumah tangga melakukan pemeriksaan payudara sendiri (SADARI). *Indones J Public Heal* 2017; 12: 143–153.
10. Sinaga CF, Ardayani T. Hubungan pengetahuan dan sikap remaja putri tentang deteksi dini kanker payudara melalui periksa payudara sendiri di SMA Pasundan 8 Bandung Tahun 2016. *Kartika J Ilm Farm* 2016; 4: 16–19.
11. Avryna P, Wahid I, Fauzar F. Invasive Carcinoma Mammae dengan Metastasis Orbita, Tulang, dan Paru. *J Kesehat Andalas* 2019; 8: 89–93.



hiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a in breast cancer: clinical utility in an era of checkpoint inhibition. *Ann Oncol* 236–1244.

13. He L, Wang Y, Wu Q, et al. Association between levels of tumor- infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes : a meta-analysis. *BMC Womens Health* 2020; 20: 1–11.
14. Dushyanthen S, Beavis PA, Savas P, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. *BMC Med* 2015; 13: 1–13.
15. Krell J, Frampton AE, Stebbing J. The clinical significance of tumor infiltrating lymphocytes in breast cancer: does subtype matter? *BMC Cancer* 2012; 12: 1–3.
16. Yu P, Fu Y-X. Tumor-infiltrating T lymphocytes: friends or foes? *Lab Investig* 2006; 86: 231–245.
17. Gu-Trantien C, Loi S, Garaud S, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. *J Clin Invest* 2013; 123: 2873–2892.
18. Sasada T, Suekane S. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. *Immunotherapy* 2011; 3: 1235–1251.
19. Droeser R, Zlobec I, Kilic E, et al. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. *BMC Cancer* 2012; 12: 1–10.
20. Simonson WTN, Allison KH. Tumour-infiltrating lymphocytes in cancer: implications for the diagnostic pathologist. *Diagnostic Histopathol* 2011; 17: 80–90.
21. Gisterek I, Frydecka I, ŚWIĄTONIOWSKI G, et al. Tumour-infiltrating CD4 and CD8 T lymphocytes in breast cancer. *Reports Pract Oncol Radiother* 2008; 13: 206–209.
22. Boissonnas A, Licata F, Poupel L, et al. CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. *Neoplasia* 2013; 15: 85-IN26.
23. Koestler DC, Marsit CJ, Christensen BC, et al. Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers. *Cancer Epidemiol biomarkers Prev* 2012; 21: 1293–1302.
24. Rathore AS, Kumar S, Konwar R, et al. Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. *ancer* 2013; 50: 239–244.



SMA, Paish EC, Powe DG, et al. An evaluation of the clinical significance of infiltrating cells in human breast cancer. *Breast Cancer Res Treat* 2011; 127: 99–

26. Tanggo VVC. *Gradasi Histopatologi Sebagai Prediktor*. Surabaya: Perpustakaan Universitas Airlangga, <http://repository.unair.ac.id/56504/> (2016).
27. Danladi C, Serakinci N. Performance of risk prediction models in breast cancer screening among women in Cyprus. *EMHJ-Eastern Mediterr Heal J* 2022; 28: 888–895.
28. Fadhil A, Hussein A, Albahadly KY, et al. Identify Breast Cancer Risk Factors Using the Gail Assessment Model in Iraq. *Razi Vaccine Serum Res Inst* 2022; 77: 1901–1907.
29. McCarthy AM, Guan Z, Welch M, et al. Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort. *J Natl Cancer Inst* 2020; 112: 489–497.
30. Abdel-razeq H, Zaru L, Badheeb A, et al. The Application of Gail Model to Predict the Risk of Developing Breast Cancer among Jordanian Women. *J Oncol*; 2020.
31. Kim J-Y, Jung EJ, Kim J-M, et al. Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. *BMC Cancer* 2020; 20: 1206.
32. American Cancer Society. *Breast Cancer Risk and Prevention Breast Cancer Risk Factors You Cannot Change*. Amerika: The American Cancer Society, 2020.
33. Brentnall AR, Cohn WF, Knaus WA, et al. A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model. *J Breast Imaging* 2019; 1: 99–106.
34. Wang L, Zhang X, Li Y, et al. Stage at diagnosis and survival outcomes in breast cancer patients in China: A retrospective cohort study. *J Clin Oncol*; 38(12), 10.
35. Gnerlich JL, Deshpande AD, Jeffe DB, et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. *J Am Coll Surg* 2009; 208: 341–347.
36. Gao Z, Li C, Liu M, et al. Predictive and prognostic role of tumour- infiltrating lymphocytes in breast cancer patients with different molecular subtypes : a meta-analysis. *BMC Ca* 2020; 20: 1–14.
37. Caldarella A, Buzzoni C, Crocetti E, et al. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. *J Cancer Res Clin Oncol* 2013; 139:



Orvieto E, Dominici M, et al. Rare breast cancer subtypes: histological, and clinical peculiarities. *Oncologist* 2014; 19: 805–813.

39. Liu Y, He M, Zuo W, et al. Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement. *Front Oncol* 2021; 11: 1–7.
40. Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. *J Clin Oncol* 2011; 29: 660–666.
41. Mukhtar RA, Yau C, Rosen M, et al. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). *Ann Surg Oncol* 2013; 20: 3823–3830.
42. Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers. *J Clin Oncol* 2019; 37: 559–569.
43. Skriver SK, Jensen MB, Knoop AS, et al. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: Analysis from a nationwide phase II DBCG trial. *Breast Cancer Res* 2020; 22: 1–8.
44. Takada K, Kashiwagi S, Asano Y, et al. Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age. *World J Surg Oncol* 2022; 20: 1–13.
45. Sathwara JA, Balasubramaniam G, Bobdey SC, et al. Sociodemographic factors and late-stage diagnosis of breast cancer in India: A hospital-based study. *Indian J Med Paediatr Oncol* 2017; 38: 277–281.
46. Mathew A, George PS, Ramadas K, et al. Sociodemographic factors and stage of cancer at diagnosis: A population-based study in South India. *J Glob Oncol* 2019; 5: 1–10.
47. Lee J, Park K, Kim H, et al. Socioeconomic factors and immune response in cancer patients: A retrospective analysis. *J Cancer Immunol*; 38(3), 245.
48. Pujani M, Jain H, Chauhan V, et al. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. *Breast Dis* 2020; 39: 61–69.



Hubungan Tumor Infiltrating Limfosit Neoadjuvant Pada Kanker Payudara.
Hasanuddin, 2023.

.. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and
the progress of adoptive cell therapy. *Front Immunol* 2023; 14: 1–9.

51. Neophytou CM, Panagi M, Stylianopoulos T, et al. The role of tumor microenvironment in cancer metastasis: Molecular mechanisms and therapeutic opportunities. *Cancers (Basel)*; 13. Epub ahead of print 2021. DOI: 10.3390/cancers13092053.
52. Wang K, Xu J, Zhang T, et al. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. *Oncotarget* 2016; 7: 44288–44298.

